Completed PHASE2 INTERVENTIONAL 1-arm NCT01569984

Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy for Colorectal Liver Metastasis (SBRT-Avastin)

An Open Label, Single-Centre, Phase II Study for Radiosensitization of AVASTIN® (Bevacizumab) With Stereotactic Body Radiotherapy (SBRT) for Colorectal Liver Metastasis (SBRT Avastin)

Sponsor: Dr. Yoo-Joung Ko

Conditions Colorectal Cancer.

Interventions Stereotactic body radiotherapy

Updated 5 times since 2017 Last updated: Oct 12, 2016 Started: Mar 31, 2012 Primary completion: Mar 31, 2015 Completion: Mar 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Colorectal Cancer. and is currently completed. Dr. Yoo-Joung Ko leads this study, which shows 5 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dr. Yoo-Joung Ko
Roche Pharma AG

Data source: Sunnybrook Health Sciences Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Toronto, Canada